DE2714751A1 - Herstellung von alpha-l-antikoerpern, reinigung von alpha-l-antigenen und reagenz fuer die bestimmung von alpha-l-antikoerpern und alpha-l-antigenen - Google Patents
Herstellung von alpha-l-antikoerpern, reinigung von alpha-l-antigenen und reagenz fuer die bestimmung von alpha-l-antikoerpern und alpha-l-antigenenInfo
- Publication number
- DE2714751A1 DE2714751A1 DE19772714751 DE2714751A DE2714751A1 DE 2714751 A1 DE2714751 A1 DE 2714751A1 DE 19772714751 DE19772714751 DE 19772714751 DE 2714751 A DE2714751 A DE 2714751A DE 2714751 A1 DE2714751 A1 DE 2714751A1
- Authority
- DE
- Germany
- Prior art keywords
- antigen
- antibody
- solution
- determination
- alpha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 title claims description 156
- 102000036639 antigens Human genes 0.000 title claims description 137
- 108091007433 antigens Proteins 0.000 title claims description 137
- 239000003153 chemical reaction reagent Substances 0.000 title claims description 41
- 238000004519 manufacturing process Methods 0.000 title claims description 5
- 238000000746 purification Methods 0.000 title description 5
- 238000000034 method Methods 0.000 claims description 84
- 241001465754 Metazoa Species 0.000 claims description 7
- 239000010419 fine particle Substances 0.000 claims description 6
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 claims description 4
- 238000004140 cleaning Methods 0.000 claims description 3
- 238000000432 density-gradient centrifugation Methods 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000000243 solution Substances 0.000 description 72
- 210000002966 serum Anatomy 0.000 description 25
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 24
- 239000007853 buffer solution Substances 0.000 description 22
- 238000001514 detection method Methods 0.000 description 20
- 210000003743 erythrocyte Anatomy 0.000 description 20
- 208000019423 liver disease Diseases 0.000 description 19
- 239000011780 sodium chloride Substances 0.000 description 18
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 18
- 235000018102 proteins Nutrition 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 12
- 239000008280 blood Substances 0.000 description 12
- 230000003053 immunization Effects 0.000 description 11
- 229910019142 PO4 Inorganic materials 0.000 description 10
- 208000006454 hepatitis Diseases 0.000 description 10
- 239000010452 phosphate Substances 0.000 description 10
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 10
- 239000008055 phosphate buffer solution Substances 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- 238000002649 immunization Methods 0.000 description 9
- 238000005119 centrifugation Methods 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 201000007270 liver cancer Diseases 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 208000014018 liver neoplasm Diseases 0.000 description 6
- WVJKHCGMRZGIJH-UHFFFAOYSA-N methanetriamine Chemical compound NC(N)N WVJKHCGMRZGIJH-UHFFFAOYSA-N 0.000 description 6
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 6
- 235000009518 sodium iodide Nutrition 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 238000002523 gelfiltration Methods 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 229920000936 Agarose Polymers 0.000 description 4
- 206010003445 Ascites Diseases 0.000 description 4
- 206010008909 Chronic Hepatitis Diseases 0.000 description 4
- 231100000354 acute hepatitis Toxicity 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 4
- 208000019425 cirrhosis of liver Diseases 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 230000035931 haemagglutination Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 3
- 239000001263 FEMA 3042 Substances 0.000 description 3
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 3
- 229920005654 Sephadex Polymers 0.000 description 3
- 239000012507 Sephadex™ Substances 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 3
- 239000000356 contaminant Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 229960000633 dextran sulfate Drugs 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000000951 immunodiffusion Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 description 3
- 229940033123 tannic acid Drugs 0.000 description 3
- 235000015523 tannic acid Nutrition 0.000 description 3
- 229920002258 tannic acid Polymers 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical class OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 241000473945 Theria <moth genus> Species 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 239000007982 barbital buffer Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- -1 erythrocytes Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000000760 immunoelectrophoresis Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 2
- 238000005185 salting out Methods 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229910021555 Chromium Chloride Inorganic materials 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 102000004641 Fetal Proteins Human genes 0.000 description 1
- 108010003471 Fetal Proteins Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- CWGJBBRZFIPXNZ-UHFFFAOYSA-N [C-]#N.Br Chemical compound [C-]#N.Br CWGJBBRZFIPXNZ-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- HFACYLZERDEVSX-UHFFFAOYSA-N benzidine Chemical compound C1=CC(N)=CC=C1C1=CC=C(N)C=C1 HFACYLZERDEVSX-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- LYQFWZFBNBDLEO-UHFFFAOYSA-M caesium bromide Chemical compound [Br-].[Cs+] LYQFWZFBNBDLEO-UHFFFAOYSA-M 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- QSWDMMVNRMROPK-UHFFFAOYSA-K chromium(3+) trichloride Chemical compound [Cl-].[Cl-].[Cl-].[Cr+3] QSWDMMVNRMROPK-UHFFFAOYSA-K 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- YCUVUDODLRLVIC-VPHDGDOJSA-N sudan black b Chemical compound C1=CC(=C23)NC(C)(C)NC2=CC=CC3=C1\N=N\C(C1=CC=CC=C11)=CC=C1\N=N\C1=CC=CC=C1 YCUVUDODLRLVIC-VPHDGDOJSA-N 0.000 description 1
- 239000010414 supernatant solution Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- LRBQNJMCXXYXIU-YIILYMKVSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)C(OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-YIILYMKVSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960001479 tosylchloramide sodium Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/82—Hepatitis associated antigens and antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/806—Antigenic peptides or proteins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
- Y10S530/83—Plasma; serum
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3792976A JPS52128212A (en) | 1976-04-05 | 1976-04-05 | Reagents for detecting alpha-l-antigen and alpha-l-antibody |
| JP3792876A JPS6026181B2 (ja) | 1976-04-05 | 1976-04-05 | α−Ｌ抗体の製造法 |
| JP3793176A JPS52128214A (en) | 1976-04-05 | 1976-04-05 | Purification of alpha-l-antigen |
| JP3793076A JPS52128213A (en) | 1976-04-05 | 1976-04-05 | Reagents for detecting alpha-l-antibody and alpha-l-antigen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE2714751A1 true DE2714751A1 (de) | 1977-10-06 |
| DE2714751C2 DE2714751C2 (OSRAM) | 1987-07-16 |
Family
ID=27460496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19772714751 Granted DE2714751A1 (de) | 1976-04-05 | 1977-04-01 | Herstellung von alpha-l-antikoerpern, reinigung von alpha-l-antigenen und reagenz fuer die bestimmung von alpha-l-antikoerpern und alpha-l-antigenen |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US4132767A (OSRAM) |
| CH (1) | CH636449A5 (OSRAM) |
| DE (1) | DE2714751A1 (OSRAM) |
| FR (1) | FR2347688A1 (OSRAM) |
| GB (1) | GB1564063A (OSRAM) |
| SE (2) | SE446128B (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4232001A (en) * | 1978-09-22 | 1980-11-04 | University Patents, Inc. | Methods and materials for detection of estrophilin |
| US4241044A (en) * | 1978-12-28 | 1980-12-23 | Abbott Laboratories | Method of diagnosing cancer by detecting elevated anti-T antibody activity |
| SE451508B (sv) * | 1979-01-30 | 1987-10-12 | Otsuka Pharma Co Ltd | Bestemning av substanser med tumorassocierade glykobindningar medelst lektiner som specifikt binder till terminala galaktos (beta 1 - 3 eller beta 1 - 4)-n-acetylglukosamin- eller -n-acetylgalaktosamingrupper samt cance |
| GB2161165A (en) * | 1984-06-12 | 1986-01-08 | Cambridge Patent Dev | Secondary antibodies |
| US5134662A (en) * | 1985-11-04 | 1992-07-28 | Cell Analysis Systems, Inc. | Dual color camera microscope and methodology for cell staining and analysis |
| US4998284A (en) * | 1987-11-17 | 1991-03-05 | Cell Analysis Systems, Inc. | Dual color camera microscope and methodology for cell staining and analysis |
| US5086476A (en) * | 1985-11-04 | 1992-02-04 | Cell Analysis Systems, Inc. | Method and apparatus for determining a proliferation index of a cell sample |
| US5109429A (en) * | 1985-11-04 | 1992-04-28 | Cell Analysis Systems,Inc. | Apparatus and method for analyses of biological specimens |
| US5962340A (en) * | 1994-11-02 | 1999-10-05 | Wako Pure Chemical Industries Ltd. | Homogeneous immunoassay method utilizing 5-300 mM magnesium |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3663684A (en) * | 1970-06-01 | 1972-05-16 | Hoffmann La Roche | Carcinoembryonic antigen and diagnostic method using radioactive iodine |
| US3867363A (en) * | 1970-06-01 | 1975-02-18 | Hans John Hansen | Carcinoembryonic antigens |
| US3697638A (en) * | 1970-06-01 | 1972-10-10 | Hoffmann La Roche | Antigens |
| US3956258A (en) * | 1972-05-12 | 1976-05-11 | Hoffmann-La Roche Inc. | Carcinoembryonic antigens |
| US3823126A (en) * | 1972-05-23 | 1974-07-09 | K Bjorklund | Process of separating human cancer antigen proteins by gel filtration |
| US3960827A (en) * | 1972-07-10 | 1976-06-01 | Bjoerklund K B | Cancer associated polypeptide antigen, process for its preparation, process for preparing antibodies, process of cancer diagnosis and composition useful as an immunizing agent |
-
1977
- 1977-03-31 US US05/783,460 patent/US4132767A/en not_active Expired - Lifetime
- 1977-04-01 DE DE19772714751 patent/DE2714751A1/de active Granted
- 1977-04-04 CH CH422777A patent/CH636449A5/de not_active IP Right Cessation
- 1977-04-04 SE SE7703918A patent/SE446128B/xx not_active IP Right Cessation
- 1977-04-05 GB GB14382/77A patent/GB1564063A/en not_active Expired
- 1977-04-05 FR FR7710273A patent/FR2347688A1/fr active Granted
-
1982
- 1982-10-18 SE SE8205891A patent/SE448032B/sv not_active IP Right Cessation
Non-Patent Citations (2)
| Title |
|---|
| MEYER: Enzyklopädisches Lexikon, Bd. 2, 1971, 322, 323 u. 330 * |
| Pschyrembel, Klinisches Wörterbuch, 1972, 65 * |
Also Published As
| Publication number | Publication date |
|---|---|
| SE448032B (sv) | 1987-01-12 |
| FR2347688A1 (fr) | 1977-11-04 |
| SE8205891L (sv) | 1982-10-18 |
| SE7703918L (sv) | 1977-10-06 |
| GB1564063A (en) | 1980-04-02 |
| CH636449A5 (de) | 1983-05-31 |
| DE2714751C2 (OSRAM) | 1987-07-16 |
| SE8205891D0 (sv) | 1982-10-18 |
| FR2347688B1 (OSRAM) | 1980-12-05 |
| US4132767A (en) | 1979-01-02 |
| SE446128B (sv) | 1986-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2029499C3 (de) | Verfahren zum Nachweis der Anwesenheit von carcinoembryonalen Antigenen im Blut | |
| CH627187A5 (OSRAM) | ||
| CH658317A5 (de) | Verfahren zur feststellung von krebs beim menschen. | |
| DE2816841A1 (de) | Radioimmunologische bestimmung von prokollagen (typ iii) und prokollagen- peptid (typ iii) | |
| DE2128670B2 (de) | Immunologische isoenzym-bestimmungsmethode | |
| EP0060491B1 (de) | Protein (PP16), Verfahren zu seiner Anreicherung und Gewinnung sowie seine Verwendung | |
| EP0013930A1 (de) | Immunogen, Antikörper für ein Thymus-Hormon, markiertes Thymus-Hormon und Verfahren zur Bestimmung dieses Thymushormons | |
| DE69031662T2 (de) | Test für die alkalische Phosphatase aus Knochen | |
| DE2714751C2 (OSRAM) | ||
| EP0101603B1 (de) | Neues Protein (PP13), Verfahren zu seiner Anreicherung und Gewinnung sowie seine Verwendung | |
| EP0014756A1 (de) | Plazentaspezifisches Gewebsprotein PP10 und Verfahren zu seiner Anreicherung | |
| DE60035267T2 (de) | Verfahren zur analyse der menge an intraabdominalem fettgewebe | |
| EP0037963B1 (de) | Neues Protein PP9, Verfahren zu seiner Gewinnung sowie seine Verwendung | |
| EP0141326B1 (de) | Neues Protein PP20, Verfahren zu seiner Gewinnung sowie seine Verwendung | |
| EP0165476A2 (de) | Gewebeprotein PP18, Verfahren zu seiner Gewinnung sowie seine Verwendung | |
| DE3410694C2 (OSRAM) | ||
| DE3887727T2 (de) | Partikelstabilisierte Epitope zur Standardisierung und Kontrolle von Immuntests. | |
| EP0029191A1 (de) | Neues Protein PP11, ein Verfahren zu seiner Gewinnung und seine Verwendung | |
| DE2814121B2 (de) | Verfahren zur Herstellung eines bei der Krebs-Diagnose verwendbaren spezifischen Immunserums | |
| DE2126128A1 (de) | Medizinisches Testverfahren, Reagens und Additiv zur Durchführung des Verfahrens | |
| EP0137345B1 (de) | Membranassoziierte Proteine (MP2), Verfahren zu ihrer Gewinnung sowie ihre Verwendung | |
| DE2062558A1 (de) | Mittel zur Diagnose von primärem Leberkrebs und Verfahren zur Her stellung desselben | |
| DE3511199A1 (de) | Verfahren zur immunologischen bestimmung von heparansulfat-proteoglykan, verfahren zur herstellung bzw. reinigung von dafuer geeignetem heparansulfat-proteoglykan aus basalmembran-haltigen geweben | |
| DE2243237A1 (de) | Nachweis der immunreaktion gegenueber krebs | |
| AT358744B (de) | Verfahren zum nachweis des alpha2-ap- -glykoproteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8110 | Request for examination paragraph 44 | ||
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |